G1 Therapeutics Q2 2023 Earnings Report

G1 Therapeutics EPS Results

• Actual EPS: $0.14
• Consensus EPS: -$0.17
• Beat/Miss: Beat by +$0.31
• One Year Ago EPS: N/A

G1 Therapeutics Revenue Results

• Actual Revenue: $42.39 million
• Expected Revenue: $28.34 million
• Beat/Miss: Beat by +$14.05 million
• YoY Revenue Growth: N/A

G1 Therapeutics Announcement Details

• Quarter: Q2 2023
• Date: 8/2/2023
• Time: N/A

G1 Therapeutics (NASDAQ:GTHX), a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.